189 related articles for article (PubMed ID: 23902965)
1. Potential new therapeutic targets for pathological pruritus.
Kuraishi Y
Biol Pharm Bull; 2013; 36(8):1228-34. PubMed ID: 23902965
[TBL] [Abstract][Full Text] [Related]
2. Systemic kappa opioid receptor agonists in the treatment of chronic pruritus: a literature review.
Phan NQ; Lotts T; Antal A; Bernhard JD; Ständer S
Acta Derm Venereol; 2012 Sep; 92(5):555-60. PubMed ID: 22504709
[TBL] [Abstract][Full Text] [Related]
3. Targeted treatment of pruritus: a look into the future.
Tey HL; Yosipovitch G
Br J Dermatol; 2011 Jul; 165(1):5-17. PubMed ID: 21219293
[TBL] [Abstract][Full Text] [Related]
4. Non-analgesic effects of opioids: peripheral opioid receptors as promising targets for future anti-pruritic therapies.
Reich A; Szepietowski JC
Curr Pharm Des; 2012; 18(37):6021-4. PubMed ID: 22747545
[TBL] [Abstract][Full Text] [Related]
5. A New Generation of Treatments for Itch.
Fowler E; Yosipovitch G
Acta Derm Venereol; 2020 Jan; 100(2):adv00027. PubMed ID: 31940047
[TBL] [Abstract][Full Text] [Related]
6. Itch Management: Treatments under Development.
Pereira MP; Ständer S
Curr Probl Dermatol; 2016; 50():71-6. PubMed ID: 27578074
[TBL] [Abstract][Full Text] [Related]
7. Pruritus and fatigue associated with liver disease: is there a role for ondansetron?
Jones EA
Expert Opin Pharmacother; 2008 Mar; 9(4):645-51. PubMed ID: 18312165
[TBL] [Abstract][Full Text] [Related]
8. [Modern systemic therapy for pruritus].
Metz M; Pereira MP
Hautarzt; 2020 Jul; 71(7):518-524. PubMed ID: 32399670
[TBL] [Abstract][Full Text] [Related]
9. Emerging Therapeutic Options for Chronic Pruritus.
Reszke R; Krajewski P; Szepietowski JC
Am J Clin Dermatol; 2020 Oct; 21(5):601-618. PubMed ID: 32607945
[TBL] [Abstract][Full Text] [Related]
10. [Mechanisms of itch and the pharmacology of anti-pruritic agents].
Kuraishi Y
Nihon Yakurigaku Zasshi; 2012 Apr; 139(4):160-4. PubMed ID: 22498680
[No Abstract] [Full Text] [Related]
11. Novel drugs for the treatment of chronic pruritus.
Pereira MP; Ständer S
Expert Opin Investig Drugs; 2018 Dec; 27(12):981-988. PubMed ID: 30426802
[TBL] [Abstract][Full Text] [Related]
12. Trp channels and itch.
Sun S; Dong X
Semin Immunopathol; 2016 May; 38(3):293-307. PubMed ID: 26385480
[TBL] [Abstract][Full Text] [Related]
13. Pruritus: still a challenge.
Cunha PR; Delfini Filho O
An Bras Dermatol; 2012; 87(5):735-41. PubMed ID: 23044567
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging systemic treatments targeting the neural system for chronic pruritus.
Golpanian RS; Yosipovitch G
Expert Opin Pharmacother; 2020 Sep; 21(13):1629-1636. PubMed ID: 32515664
[TBL] [Abstract][Full Text] [Related]
15. Neurophysiological and neurochemical basis of modern pruritus treatment.
Ständer S; Weisshaar E; Luger TA
Exp Dermatol; 2008 Mar; 17(3):161-9. PubMed ID: 18070080
[TBL] [Abstract][Full Text] [Related]
16. Leukotriene B(4) mediates sphingosylphosphorylcholine-induced itch-associated responses in mouse skin.
Andoh T; Saito A; Kuraishi Y
J Invest Dermatol; 2009 Dec; 129(12):2854-60. PubMed ID: 19657356
[TBL] [Abstract][Full Text] [Related]
17. Medical treatment of pruritus.
Ständer S; Weisshaar E
Expert Opin Emerg Drugs; 2012 Sep; 17(3):335-45. PubMed ID: 22870909
[TBL] [Abstract][Full Text] [Related]
18. Advances in therapeutic strategies for the treatment of pruritus.
Stull C; Lavery MJ; Yosipovitch G
Expert Opin Pharmacother; 2016; 17(5):671-87. PubMed ID: 26630350
[TBL] [Abstract][Full Text] [Related]
19. Chronic Pruritus: Current and Emerging Treatment Options.
Pereira MP; Ständer S
Drugs; 2017 Jun; 77(9):999-1007. PubMed ID: 28466423
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for the treatment of pruritus.
Ständer S; Weisshaar E; Raap U
Expert Opin Emerg Drugs; 2015 Sep; 20(3):515-21. PubMed ID: 26027744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
